Anders Engeland1,2, Tone Bjørge2,3, Kari Klungsøyr1,2, Vidar Hjellvik1, Svetlana Skurtveit1,4, Kari Furu1. 1. Division of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway. 2. Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. 3. Cancer Registry of Norway, Oslo, Norway. 4. Norwegian Centre for Addictive Research, University of Oslo, Oslo, Norway.
Abstract
PURPOSE: To explore trends in use of maternal medication 3 months prior to, during and 3 months after pregnancy. METHODS: Data on births from the Medical Birth Registry of Norway were linked to the Norwegian Prescription Database, identifying women's use of medications around pregnancy. All women giving birth in Norway during 2005 to 2015 (638 532 singleton births to 414 567 women) were included. Proportions of pregnant women using different medications in association with pregnancy, and annual relative change in medication use during 2005 to 2015, were calculated. RESULTS: In Norway, 60% of pregnant women used prescription medications during pregnancy (2005-15), increasing from 57% in 2005 to 62% in 2015. The annual relative increase was 0.9% (95% CI: 0.8-1.0). In the first trimester, approximately 17% of the women used medications regarded as potentially teratogenic during 2005 to 2015, increasing from 15% to 19%. Overall, this proportion was higher in the first than in the second (8.9%) and third (8.0%) trimesters, and higher than in the 3 months after pregnancy (14%). The annual relative increase of medications regarded as potentially teratogenic in the first trimester was 2.5% (95% CI: 2.3-2.7). CONCLUSIONS: The proportion of women using potentially teratogenic medications in the first trimester of pregnancy have increased during the last decade. Clinicians need to be aware of the possibility of pregnancy when prescribing potentially teratogenic medication to women of fertile age and focus this in the consultations. The increasing trends call for the need of routine surveillance of adverse birth outcomes linked to medication use in pregnancy.
PURPOSE: To explore trends in use of maternal medication 3 months prior to, during and 3 months after pregnancy. METHODS: Data on births from the Medical Birth Registry of Norway were linked to the Norwegian Prescription Database, identifying women's use of medications around pregnancy. All women giving birth in Norway during 2005 to 2015 (638 532 singleton births to 414 567 women) were included. Proportions of pregnant women using different medications in association with pregnancy, and annual relative change in medication use during 2005 to 2015, were calculated. RESULTS: In Norway, 60% of pregnant women used prescription medications during pregnancy (2005-15), increasing from 57% in 2005 to 62% in 2015. The annual relative increase was 0.9% (95% CI: 0.8-1.0). In the first trimester, approximately 17% of the women used medications regarded as potentially teratogenic during 2005 to 2015, increasing from 15% to 19%. Overall, this proportion was higher in the first than in the second (8.9%) and third (8.0%) trimesters, and higher than in the 3 months after pregnancy (14%). The annual relative increase of medications regarded as potentially teratogenic in the first trimester was 2.5% (95% CI: 2.3-2.7). CONCLUSIONS: The proportion of women using potentially teratogenic medications in the first trimester of pregnancy have increased during the last decade. Clinicians need to be aware of the possibility of pregnancy when prescribing potentially teratogenic medication to women of fertile age and focus this in the consultations. The increasing trends call for the need of routine surveillance of adverse birth outcomes linked to medication use in pregnancy.
Authors: Vinoj H Sewberath Misser; Arti Shankar; Ashna Hindori-Mohangoo; Jeffrey Wickliffe; Maureen Lichtveld; Dennis R A Mans Journal: Adv Pharmacoepidemiol Drug Saf Date: 2021-09-20
Authors: Alana Cavadino; Lovisa Sandberg; Inger Öhman; Tomas Bergvall; Kristina Star; Helen Dolk; Maria Loane; Marie-Claude Addor; Ingeborg Barisic; Clara Cavero-Carbonell; Ester Garne; Miriam Gatt; Babak Khoshnood; Kari Klungsøyr; Anna Latos-Bielenska; Nathalie Lelong; Reneé Lutke; Anna Materna-Kiryluk; Vera Nelen; Amanda Nevill; Mary O'Mahony; Olatz Mokoroa; Anna Pierini; Hanitra Randrianaivo; Anke Rissmann; David Tucker; Awi Wiesel; Lyubov Yevtushok; Joan K Morris Journal: Drug Saf Date: 2021-05-09 Impact factor: 5.606
Authors: Arash Derakhshan; Robin P Peeters; Peter N Taylor; Sofie Bliddal; David M Carty; Margreet Meems; Bijay Vaidya; Liangmiao Chen; Bridget A Knight; Farkhanda Ghafoor; Polina V Popova; Lorena Mosso; Emily Oken; Eila Suvanto; Aya Hisada; Jun Yoshinaga; Suzanne J Brown; Judit Bassols; Juha Auvinen; Wichor M Bramer; Abel López-Bermejo; Colin M Dayan; Robert French; Laura Boucai; Marina Vafeiadi; Elena N Grineva; Victor J M Pop; Tanja G Vrijkotte; Leda Chatzi; Jordi Sunyer; Ana Jiménez-Zabala; Isolina Riaño; Marisa Rebagliato; Xuemian Lu; Amna Pirzada; Tuija Männistö; Christian Delles; Ulla Feldt-Rasmussen; Erik K Alexander; Scott M Nelson; Layal Chaker; Elizabeth N Pearce; Mònica Guxens; Eric A P Steegers; John P Walsh; Tim I M Korevaar Journal: Lancet Diabetes Endocrinol Date: 2020-06 Impact factor: 44.867
Authors: Satu-Maarit Björkstedt; Hannu Kautiainen; Ulla Tuomi; Mika Gissler; Pirjo Pennanen; Johan G Eriksson; Merja K Laine Journal: Sci Rep Date: 2021-02-24 Impact factor: 4.379